摘要
目的:探讨己酮可可碱对急性缺血性卒中患者头晕/眩晕症状的治疗效果。方法:选取2020年6月~2022年1月期间全国38家医院1202例急性缺血性卒中合并头晕/眩晕症状患者,其中14例不符合纳入标准,99例随访期间疗效指标缺失,最终纳入1089例,采用配对分组方法分为对照组(n=532)与观察组(n=557)。对照组给予急性缺血性卒中基础用药,观察组在对照组基础上加用己酮可可碱缓释片,连续用药4周或至头晕/眩晕缓解后3天。比较两组眩晕评定量表(DARS)评分、视觉模拟评分法(VAS)评分、改良Rankin量表(m RS)评分及不良反应的发生情况。结果:治疗1周后,两组DARS评分0~3分比率比较无统计学差异(P>0.05);治疗4周后,观察组DARS评分为0~3分的比率(81.1%)高于对照组(63.5%,P<0.05)。治疗4周后,两组DARS评分均较基线降低(P<0.05),且观察组DARS评分低于对照组(P<0.05)。治疗1周及4周后,观察组VAS评分为0~1分的比率均高于对照组(P<0.05);治疗4周后,两组VAS评分均较基线降低(P<0.05),且观察组VAS评分低于对照组(P<0.05)。治疗4周后,观察组m RS≤1分的患者比率(91.4%)高于对照组(86.1%,P<0.05)。两组不良反应总发生率比较无统计学差异(P>0.05)。结论:己酮可可碱可改善急性缺血性卒中患者头晕/眩晕症状,且安全性良好。
Objective:To investigate the efficacy of pentoxifylline in the treatment of acute ischemic stroke related-dizziness/vertigo.Methods:1202 acute ischemic stroke related-dizziness/vertigo patients admitted from June 2020 to January 2022 by 38 hospitals in China were included in this study,with 14 patients ineligible and 99 patients lacking of efficacy data of follow-up period.Finally,1089 patients were enrolled.The patients were divided into control group(n=532)and observation group(n=557)using paired comparison method.The control group was given conventional drugs for acute ischemic stroke,and the observation group was given pentoxifylline sustained-release tablets in combination with the drugs used in the control group for 4 weeks or until 3 days after dizziness/vertigo was relieved.Dizziness assessment rating scale(DARS),visual analog scale(VAS),modified Rankin scale(mRS)and the incidence of adverse events were compared between the two groups.Results:The rate of 0~3 DARS score at Week 1 showed no statistically significant difference between the two groups(P>0.05);The rate of DARS score 0~3 at Week 4 was significantly higher in the observation group than in the control group(81.1%vs 63.5%,P<0.05).The DARS score in both groups decreased from the baseline at Week 4(P<0.05),with the observation group being significantly lower than that of the control group(P<0.05).The rate of 0~1 VAS score in the observation group was significantly higher than that in the control group both at Week 1 and Week 4(P<0.05).The VAS score in both groups decreased from the baseline at Week 4(P<0.05),with the observation group being significantly lower than that of the control group(P<0.05).The percentage of patients with mRS≤1 at Week 4 was significantly higher in the observation group than that in the control group(91.4%vs 86.1%,P<0.05).In addition,the incidence of total adverse events was not significantly different between the two groups(P>0.05).Conclusion:Pentoxifylline can improve the AIS related-dizziness/vertigo,and the safety prof
作者
尹延伟
陈大伟
张光运
杨芬
赵发国
李文平
赵聪
张振
张微微
石进
YIN Yan-wei;CHEN Da-wei;ZHANGGuang-yun;YANG Fen;ZHAO Fa-guo;LI Wen-ping;ZHAO Cong;ZHANGZhen;ZHANG Wei-wei;SHI Jin(Department of Neurology,Air Force Medical Center,Beijing 100142,China;Department of Neurology,Seventh Medical Center,PLA General Hospital,Beijing 100010,China)
出处
《中国合理用药探索》
CAS
2023年第9期57-65,共9页
Chinese Journal of Rational Drug Use
关键词
卒中
脑梗死
头晕
眩晕
己酮可可碱
stroke
cerebral infarction
dizziness
vertigo
pentoxifylline
